V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 210031524 | 210013802 | 1.66 | 69.3 | Curative (C) | 2016-01-17 | 2016-09-18 | CYCLOPHOSPHAMIDE + ETOPOSIDE + Procarbazine | N | N | 210029535 | ICE-R |
| 210031525 | 210013807 | 1.68 | 50 | Curative (C) | 2015-01-29 | 2015-10-06 | Bevacizumab + Irinotecan | N | null | 210029666 | CYCLO + FLUDARABINE + RITUXIMAB |
| 210031526 | 210013812 | null | 55 | Curative (C) | 2016-02-25 | 2016-03-25 | CLARITY Trial | 02 | N | 210030019 | PENTOSTATIN + RITUXIMAB |
| 210031527 | 210022624 | 1.72 | 0 | Disease modification (D) | 2018-05-21 | 2018-06-25 | Alemtuzumab + Cyclophos TBI Allo | null | N | 210030225 | OFATUMUMAB |
| 210031528 | 210022626 | 1.75 | 81.8 | Curative (C) | 2018-06-28 | 2018-06-28 | Packer Maintenance Regimen | 02 | null | 210030276 | BORTEZOMIB + PANOBINOSTAT |
| 210031529 | 210013816 | 1.83 | 87.6 | Curative (C) | 2019-04-27 | 2019-04-30 | CLL210 TRIAL | N | N | 210030452 | CAPECITABINE |
| 210031530 | 210028196 | null | 45.3 | Curative (C) | 2018-09-15 | 2018-09-15 | CARBOPLATIN + ETOPOSIDE + IFOSFAMIDE | 02 | N | 210030490 | CARBOPLATIN + PROCARBAZINE |
| 210031531 | 210013817 | 0 | 52.3 | null | 2018-10-24 | 2018-10-28 | CYCLOPHOSPHAMIDE + RITUXIMAB + VINCRISTINE | 2 | N | 210030551 | ALL INDUCTION |
| 210031532 | 210013821 | 1.64 | 69 | Curative (C) | 2013-09-14 | 2014-10-03 | Nilotinib | N | N | 210030605 | LENALIDOMIDE |
| 210031533 | 210013824 | 1.63 | 35.5 | Curative (C) | 2017-10-05 | 2017-10-12 | CVP | 2 | N | 210030823 | CYTARABINE |
| 210031534 | 210013825 | 1.62 | null | Disease modification (D) | 2016-04-04 | 2016-04-04 | BR14 TRIAL | N | N | 210030851 | CLOFARABINE + CYCLOPHOSPHAMIDE + ETOPOSIDE |
| 210031535 | 210013828 | 1.89 | 63 | Disease modification (D) | 2017-07-02 | 2017-07-14 | TRASTUZUMAB | N | N | 210030882 | CYTARABINE HD + METHOTREXATE HD |
| 210031536 | 210022635 | 0 | 98.6 | Curative (C) | 2016-05-18 | 2016-08-11 | CYCLOPHOSPHAMIDE + RITUXIMAB + VINCRISTINE | 02 | N | 210031032 | ABIRATERONE |
| 210031537 | 210028200 | null | 75.3 | Curative (C) | 2017-04-21 | 2017-04-25 | Mitomycin Intravesical | 2 | N | 210031092 | UKALL 60+ TRIAL |
| 210031538 | 210013835 | 0 | 77 | Curative (C) | 2016-11-23 | 2016-12-28 | Mini BEAM | 02 | N | 210031093 | ALL MAINTENANCE |
| 210031539 | 210013840 | 1.6 | 87.9 | Curative (C) | null | 2017-03-30 | FLUOROURACIL | 2 | N | 210031205 | ALL INTENSIFICATION MTX |
| 210031540 | 210013844 | 1.78 | 79.4 | Palliative (P) | 2018-07-18 | 2018-08-07 | Fludarabine oral | 02 | N | 210031222 | CYCLET |
| 210031541 | 210031578 | 1.68 | 12.2 | Palliative (P) | 2016-04-29 | 2016-06-08 | PACLITAXEL | 2 | N | 210031222 | IDARUBICIN |
| 210031542 | 210013845 | null | 15 | Curative (C) | 2017-07-25 | 2018-04-28 | CYTARABINE + ETOPOSIDE | 2 | null | 210031422 | CLARITY TRIAL |
| 210031543 | 210022642 | 0 | 75.6 | Disease modification (D) | 2017-05-18 | 2017-06-06 | Docetaxel 75mg/m2 (21 day) | N | N | 210031422 | OFATUMUMAB |
| 210031544 | 210013846 | 1.5 | 82.3 | Not known (9) | null | 2019-09-14 | FCR IV - Cycle 2 onwards | Y | N | 210031442 | CYCLO + FLUDARABINE + RITUXIMAB |
| 210031545 | 210022645 | 1.68 | 66.7 | Curative (C) | 2016-12-06 | 2016-12-13 | CYCLOPHOSPHAMIDE + ETOPOSIDE + NELARABINE | N | N | 210031596 | AML19 TRIAL |
| 210031546 | 210013854 | null | null | Curative (C) | null | 2016-05-04 | TAMIGA trial | N | null | 210031768 | CARBOPLATIN + PACLITAXEL |
| 210031547 | 210022649 | 1.77 | 91.8 | Curative (C) | 2017-09-19 | 2017-12-26 | MERCAPTOPURINE + METHOTREXATE + VINCRISTINE | N | N | 210031869 | BORTEZOMIB + PANOBINOSTAT |
| 210031548 | 210022652 | null | 69.95 | Curative (C) | null | 2017-04-10 | NHL 2003 Gp C M2 & 4 | 2 | null | 210032099 | NILOTINIB |
| 210031549 | 210013864 | 1.61 | null | Disease modification (D) | 2018-01-07 | 2018-03-03 | Nilotinib | N | null | 210032185 | DHAP |
| 210031550 | 210013865 | 1.73 | 82.3 | Curative (C) | 2015-06-01 | 2015-06-01 | FLUDARABINE | 02 | N | 210032314 | GEMCARBO |
| 210031551 | 210013869 | null | 64.8 | Curative (C) | null | 2019-01-27 | Docetaxel 75mg/m2 (21 day) | N | N | 210032409 | UKALL 60+ TRIAL |
| 210031552 | 210022656 | 1.08 | 73.1 | Disease modification (D) | 2019-04-21 | 2019-04-29 | CARBOPLATIN + ETOPOSIDE + THIOTEPA | Y | N | 210032604 | ALL MAINTENANCE |
| 210031553 | 210013875 | 1.71 | 82.3 | Disease modification (D) | 2016-09-16 | 2016-09-16 | Trastuzumab Subcutaneous | null | N | 210032710 | ALL MAINTENANCE |
| 210031554 | 210013877 | 1.6 | 53 | Curative (C) | 2018-01-29 | 2018-01-29 | Bevacizumab + LOMUSTINE | N | Y | 210032994 | DOCETAXEL |
| 210031555 | 210028217 | 1.77 | 76 | Curative (C) | 2017-09-21 | 2017-10-13 | GEMCITABINE | N | Y | 210033021 | ALL INDUCTION |
| 210031556 | 210028217 | 1.83 | 112.8 | Curative (C) | 2006-05-22 | 2017-07-26 | Cytarabine Intrathecal (any age) | N | Y | 210033021 | MITOMYCIN |
| 210031557 | 210013880 | null | 60.8 | Curative (C) | 2016-06-01 | 2016-06-12 | CYTARABINE | 02 | N | 210033199 | MITOMYCIN |
| 210031558 | 210013888 | 1.85 | 98.9 | Curative (C) | 2018-07-26 | 2018-08-25 | CLL210 TRIAL | N | N | 210033602 | CYCLOPHOSPHAMIDE + ETOPOSIDE + NELARABINE |
| 210031559 | 210022667 | 1.53 | null | Curative (C) | 2019-06-17 | 2019-06-22 | Gemcitabine weekly | 02 | N | 210033677 | FLUDARABINE |
| 210031560 | 210013895 | null | 46 | Disease modification (D) | 2017-10-03 | 2017-12-05 | FLUDARABINE + MELPHALAN | N | null | 210033710 | CTD |
| 210031561 | 210013896 | null | 105.9 | Curative (C) | 2017-06-30 | 2017-07-11 | NHL 2003 Gp C M3 | 02 | N | 210033781 | CAPECITABINE |
| 210031562 | 210013899 | 1.84 | 98 | Disease modification (D) | 2019-01-10 | 2019-01-10 | Lenalidomide 25mg (Cycle 1 to 25) | N | N | 210033837 | CYTARABINE + ETOPOSIDE |
| 210031563 | 210013902 | 1.66 | 64.1 | Curative (C) | 2018-08-07 | 2018-08-08 | Packer Maintenance Regimen | N | Y | 210033864 | CYTARABINE INTRATHECAL |
| 210031564 | 210013911 | 1.9 | 89 | null | 2019-11-09 | 2019-11-09 | Nilotinib | N | N | 210034315 | MELPHALAN |
| 210031565 | 210013915 | 1.62 | 70.8 | Curative (C) | 2013-02-25 | 2016-05-18 | Cytarabine intrathecal | N | N | 210034385 | BOSUTINIB |
| 210031566 | 210013917 | 1.72 | 30.2 | Disease modification (D) | 2018-12-01 | 2018-12-31 | CYCLOPHOSPHAMIDE + ETOPOSIDE + VINCRISTINE | N | N | 210034391 | CYCLOPHOSPHAMIDE HIGH DOSE |
| 210031567 | 210013922 | 0 | 61 | Neo-adjuvant (N) | 2015-08-08 | 2015-09-15 | Mitomycin Intravesical | 02 | null | 210034650 | IVAC |
| 210031568 | 210013923 | 1.62 | 39.1 | Disease modification (D) | null | 2018-04-26 | AML18 PILOT TRIAL | N | N | 210034878 | ALL MAINTENANCE |
| 210031569 | 210028230 | 1.6 | 64.3 | Curative (C) | 2015-04-16 | 2015-05-01 | Abiraterone | 2 | N | 210034999 | CVD |
| 210031570 | 210013926 | null | null | Disease modification (D) | 2016-04-25 | 2016-05-10 | Dactinomycin + Vincristine | N | null | 210035018 | NILOTINIB |
| 210031571 | 210013929 | 1.77 | 26.6 | null | 2018-02-09 | 2018-05-04 | Fludarabine IV | 2 | N | 210035201 | HYDROXYCARBAMIDE |
| 210031572 | 210013936 | 1.78 | 54 | Palliative (P) | 2019-02-19 | 2019-03-27 | DAUNORUBICIN + VINCRISTINE | 2 | N | 210035396 | ALEMTUZUMAB + CYCLOPHOSPHAMIDE |
| 210031573 | 210033722 | 1.8 | 64 | Curative (C) | 2017-04-18 | 2017-07-26 | Nilotinib | N | N | 210035468 | CYCLO + FLUDARABINE + RITUXIMAB |